International Journal of Clinical Research

Objective To discuss the clinical value of using dapagliflozin treatment in patients with heart failure. Methods 80 patients with heart failure treated in our hospital from October 2021 to October 2022 were selected and randomly divided into two groups: a control group (40 cases, traditional anti heart failure treatment) and a study group (40 cases, traditional anti heart failure treatment+dapagliflozin treatment). The main indicators for evaluating the therapeutic effect are the patients heart function, inflammation level, and treatment effect after treatment. Results Compared with the control group, the study group had LVIDs after treatment LVIDd and IL-6 CRP is lower, LVEF level, 6-minute walking distance estimation, and treatment effectiveness were higher (P<0.05). Conclusion The use of dapagliflozin in traditional treatment for heart failure patients can significantly improve their cardiac function, reduce their inflammatory response, improve overall treatment efficacy, and thus prevent the risk of disease recurrence in patients.

Heart failure; Daglizin; Cardiac function index; Indicators of inflammation